Skip to main content
PMC home page
Molecular Cancer logoLink to Molecular Cancer
. 2010 Jan 10;9:4. doi: 10.1186/1476-4598-9-4

Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways

Yi-Lan Zhang 1,2,4,#, Jiang Li 1,2,4,#, Hao-Yuan Mo 3, Fang Qiu 3, Li-Min Zheng 1,2,4, Chao-Nan Qian 1,3, Yi-Xin Zeng 1,2,4,✉
PMCID: PMC2818695  PMID: 20064222

Abstract

Background

Increasing amounts of evidence indicate that tumor infiltrating lymphocytes (TIL) are correlated with the prognosis of cancer patients. This study focuses on the association between the densities of tumor infiltrating cytotoxic T lymphocytes (CTL), activated CTL, regulatory T lymphocytes (Treg) and Th17 lymphocytes, and the prognosis and clinicopathological features of nasopharyngeal carcinoma (NPC) patients.

Results

Double immunohistochemical staining was performed in 106 biopsy specimens from newly diagnosed NPC patients. Prognostic values of infiltrating lymphocyte densities were evaluated by Kaplan-Meier analysis and Cox regression. The density of CD8+ TIL was positively correlated with lymph node metastasis, while the density of Foxp3+ TIL was negatively associated with T stage (P < 0.05). For survival evaluation, the density of Foxp3+ TIL or Foxp3+ TIL combined with GrB+ TIL together was associated with better overall survival (OS) and progression-free survival (PFS) (P < 0.01) in all patients and in the patients with late-stage diseases (Stages III and IV, P < 0.01). Meanwhile a low density of CD8+TIL or high ratio of FOXP3+TIL to CD8+TIL was correlated with better PFS in early stage patients (Stages I and II, P < 0.05). No significant association was found between IL-17+ TIL and clinicopathological characteristic or survival of NPC patients.

Conclusions

Our study identifies for the first time the tumor infiltrating Foxp3+ TIL as an independent favorable factor in the prognosis of NPC patients, especially for the patients with late-stage diseases.

Background

Nasopharyngeal carcinoma (NPC) is an epithelial neoplasm with high incidence in South China and South Asia, while with low incidence in most countries. There are three histological classficiation for NPC: Type 1, keratinising squamous-cell carcinoma; Type 2, Non- keratinising squamous-cell carcinoma; Type 3, Undifferetiation nasopharyngeal carcinoma. Due to the less symptoms and the difficulty to make clinical examination of nasopharynx, most patients with this disease are diagnosed only when the tumour at the advanced stage. Radiotherapy and concomitant chemoradiotherapy can improve overall survival and progression-free survival in NPC patients, but the prognosis remains poor in a significant number of patients with late-stage disease [1-4].

EBV infection positivity has been identified in most undifferentiated NPC (95%) by the expression of EBV latent phase antigens in the tumor cells including LMP1 (40-60%), LMP2, EBNA1 and BARF0. In addition, a large number of tumor infiltrating lymphocytes (TIL) are found around the NPC tumor tissues [5-8]. The majority of the cells in the tumor are reactive and consist predominantly of T cells with variable numbers of other inflammatory cells [9]. The presence of TIL correlates with an better prognosis in patients with several types of cancer, and each T lymphocyte subset has a unique role in the antitumor response [10-14]. Presence of tumor infiltrating cytotoxic T lymphocytes (CTL) has been linked to better patient survival in endometrial, ovarian, pancreatic and colorectal cancers [15-17]. Regulatory T cells (Treg) play an essential role in controlling immune responses to self and non-self antigens. It has been reported that the tumor infiltrating Treg cells are associated with a poorer prognosis in some cancers by suppressing the proliferation of effector T lymphocyte (i.e., cytotoxic T lymphocyte (CTL)) to prohibit an adequate tumor-specific immune response, thus enabling tumor growth [18-23]. In contrast, other researchers have reported that the tumor infiltrating Treg cells are either linked to a better prognosis or did not affect prognosis in some malignancies such as follicular lymphoma and squamous cell carcinoma [24-26]. However, the characteristics and functions of the TIL in NPC are still poorly understood. With advances in immunological techniques, adoptive immunotherapy is becoming a preferred choice with better tolerance. However, the clinical benefit of EBV-specific CTL-based adoptive immunotherapy is only observed in a small number of NPC patients, maybe due to tumor immune evasion or immune suppression of the tumor microenvironment [27,28]. Therefore it is important to understand the characteristics and functions of TIL and their relationship with tumor clinicopathological features and prognosis, as well as their potential role in immunotherapy of NPC.

In the present study, we aimed to evaluate the subsets of TIL including CTL, activated CTL, Treg, and Th17 cells by CD8/Foxp3, GrB/Foxp3 and Foxp3/IL-17 double IHC staining in 106 paraffin-embedded NPC tumor tissues. We correlated the densities of CD8+ CTL, GrB+ activated CTL, Foxp3+ Treg and IL-17+ Th17 cells with the clinical factors and outcomes in all NPC patients as well as in the patients with different disease stages. Furthermore, we evaluated the ratio of tumor infiltrating CD8+ cells to Foxp3+ cells (the ratio of CD8/Foxp3) and Foxp3+ cells together with GrB + cells in predicting survival in all patients as well as in the patients with different disease stage.

Results

Patient Characteristics

Among the 106 patients, 84 (79.2%) were male, and the median age was 49 years (range: 22-73 years). Ninety-two patients (86.8%) were with histological type III (undifferentiated) NPC, 13 (12.3%) were with type II (non-keratinizing) NPC, and only 1 (0.9%) was with type I (squamous cell carcinoma) disease. Fifty-five (47.4%) of the tumor tissues were positively stained for EBV LMP1 antigen. Of these 106 patients, only 5 (4.7%) cases were with distant metastases before treatment, and 88 (83%) were with lymph node spreading diseases (N1-N3). Thirty eight (35.9%) patients were in early disease stages (I and II) while 68 (64.2%) were in late disease stages (III and IV) at initial diagnosis. From the total number of patients, 30 (28.3%) had dead and 37 (34.9%) presented with disease progression during the follow-up for five years. Detailed clinical information is shown in Table 1, and detailed clinical and treatment information for each patient is shown in additional file 1.

Table 1.

Clinical characteristics of 106 patients with NPC

Characteristics No. (%)
Age, years
Median 49
Range 22-73
Gender
Male 84 (79.2)
Female 22 (20.8)
Tumor (T) stage
T1 24 (22.6)
T2 33 (31.1)
T3 33 (31.1)
T4 16 (15.1)
Lymphoid Nodal (N) status
N0 18 (17.0)
N1 46 (43.4)
N2 36 (29.2)
N3 11 (10.4)
Distant metastasis (M) status
M0 101 (95.3)
M1 5 (4.7)
TNM stage
I 6 (5.7)
II 32 (30.2)
III 39 (36.8)
IVa+IVb 29 (27.4)
Progression
No 69 (65.1)
Yes 37 (34.9)
Death
No 76 (71.7)
Yes 30 (28.3)
Histological type*
Type I 1 (0.9)
Type II 13 (12.3)
Type III 92 (86.8)
LMP1
Positive 47 (44.3)
Negative 56 (52.8)
Missing 3(2.8)
Open in a new tab

* Type I: squamous cell carcinoma; Type II: non-keratinizing carcinoma; Type III: undifferentiated carcinoma

The characteristics of the immunochemical variables and their relationship with NPC clinicopathological features

To characterize the subsets of TIL in NPC tissues, we defined the different lymphocyte subsets by specific antibodies: CD8 for CTL, Granzyme B (GrB) for activated CTL, Foxp3 for Tregs and IL-17 for Th17 cells. The CD8 immunostaining demonstrated cytomembrane staining in a subset of TIL around the tumor nests (Fig 1A). The median number of CD8+ cells was 52.50 ± 4.97 cells/high-power field (HPF) and the range was 0.80-231.30 cells/HPF. GrB immunostaining showed a cytoplasmic pattern (Fig 1B) in a subset of lymphocytes in tumor tissues. The median number of GrB+ cells was 32.45 ± 3.01 cells/HPF, and the range was 0.40-160.60 cells/HPF. Foxp3 immunostaining demonstrated nuclear staining in a subset of lymphocytes around tumor tissues (Fig 1A, B, and 1C). The median number of Foxp3+ cells was 87.23 ± 5.50 cells/HPF, and the range was 5.20-322.80 cells/HPF. IL-17 immunostaining established a cytoplasmic pattern (Fig 1C) in a small subset of lymphocytes around tumor tissues. The median number of IL-17+ cells was 5.60 ± 2.36 cells/HPF and the range was 0.00-150.00 cells/HPF. The CD8/Foxp3 double positive subset (Fig 1A) showed a median number of 0.9 ± 0.16 cells/HPF and a range of 0.00-9.30 cells/HPF in TIL. The Foxp3/GrB double positive subset (Fig 1B) showed a median number of 1.8 ± 0.38 cells/HPF and a range of 0.01-22.80 cells/HPF in TIL (Table 2). By general logical linear regression analysis, no significant correlation was found between the densities of any two types of lymphocytes in the present study.

Figure 1.

Figure 1

Open in a new tab

Double immunohistochemical staining for CD8/Foxp3, Foxp3/GrB and Foxp3/IL-17. A. NPC tumor tissue with numerous CD8+ (red) and Foxp3+ (brown) cells (× 200). B. NPC tumor tissue with numerous Foxp3+ (brown) and GrB+ (red) cells (× 200). C. NPC tumor tissue with numerous Foxp3+ (red) and IL-17+ (brown) cells (× 200). The staining patterns show that CD8 is on the cell membrane, GrB and IL-17 are in the cytoplasm, and Foxp3 is in the nucleus. There are a few CD8+Foxp3+ and Foxp3+GrB+ cells, but no Foxp3+IL-17+ cells.

Table 2.

Descriptive statistics of immunohistochemical variables

Variable* Mean SE Median Range
CD8+ TIL 68.24 4.97 52.50 0.80-231.30
Foxp3+ TIL 82.21 5.45 74.00 5.20-322.80
Granzyme B+ TIL 39.98 3.01 32.45 0.40-160.60
IL17+ TIL 14.75 2.36 5.60 0.00-150.00
CD8+Foxp3+ TIL 1.40 0.16 0.90 0.00-9.30
Granzyme B+ Foxp3+ TIL 3.10 0.38 1.80 0.00-22.80
Open in a new tab

Note: *Number of TIL per field (×400).

To investigate the association between the density of different types of lymphocytes and clinical features in NPC patients, the median density of each type lymphocyte was used to separate the patients into high and low TIL groups. The density of CD8+ TIL was positively associated with lymphoid nodal status in NPC patients (P = 0.038) while the densities of GrB and Foxp3-positive cells were negatively associated with the T stage (P < 0.01). The density of GrB+TIL was negatively associated with the age of patients (P = 0.011) and the density of Foxp3+TIL was negatively associated with NPC clinical stage (TNM stage, P = 0.043). No correlation was found between the density of IL-17+ TIL and the NPC patient clinicopathological characteristics. No significant association was observed between any lymphocyte variables and LMP1 expression in NPC tumor cells (Table 3).

Table 3.

Association of the CD8+, Granzyme B+, Foxp3+ or IL17+ TIL number and clinicopathological characteristics in NPC patients

Characteristics CD8 Positive Granzyme B Positive Foxp3 Positive IL17 Positive
≤52.50
(n = 53)		 > 52.50
(n = 53)		 P ≤32.45
(n = 53)		 > 32.45
(n = 53)		 P ≤74.00
(n = 53)		 >74.00
(n = 53)		 P ≤5.60
(n = 54)		 >5.60
(n = 52)		 P
Age, years
≤49 27 27 21 34 24 31 27 28
>49 26 25 0.846 32 19 0.011* 29 22 0.174 27 24 0.692
Gender
Male 41 43 41 43 39 44 42 42
Female 12 10 0.632 12 10 0.632 14 8 0.359 12 10 0.704
Tumor (T) stage
T1+T2 28 29 22 35 21 36 26 31
T3+T4 25 24 0.846 31 18 0.011* 32 17 0.003* 28 21 0.236
Lymphoid Nodal (N) status
N0 13 5 9 9 10 8 9 9
N1-3 40 48 0.038* 44 44 1.000 43 45 0.605 45 43 0.930
TNM Clinical stage
I+II 21 17 16 22 14 24 15 23
III+IVa+IVb 32 36 0.418 37 31 0.224 38 29 0.043* 39 29 0.077
LMP1
- 25 31 30 26 28 28 31 25
+ 27 20 0.195 22 25 0.494 23 24 0.914 21 26 0.280
Open in a new tab

*P < 0.05, as determined by the Pearson chi2 test.

No correlation was shown between the density of the subset of co-expression of GrB+ and Foxp3+ TIL and clinicopathological characteristics, however the density of CD8+Foxp3+TIL was positively associated with the lymphoid nodal status (P = 0.006) and increasing age (P = 0.041, Table 4). Finally, no co-expression of IL-17 and Foxp3 was found in NPC TIL by double immunohistochemical staining (data not shown).

Table 4.

The association of the number of CD8+ Foxp3+ TIL, Foxp3+ Granzyme B+ TIL and the ratio of CD8+ Foxp3+ to CD8+ and GranzymeB+ Foxp3+ to Foxp3 TIL and clinicopathological characteristics in NPC patients

Characteristics CD8+Foxp3+ Granzyme B+Foxp3+
≤0.90
(n = 53)		 > 0.90
(n = 53)		 P ≤1.80
(n = 54)		 > 1.80
(n = 52)		 P
Age, years
≤49 24 31 26 29
> 49 29 22 0.174 28 23 0.432
Gender
Male 39 45 42 42
Female 14 8 0.151 12 10 0.704
Tumor (T) stage
T1+T2 25 32 29 28
T3+T4 28 21 0.173 25 24 0.988
Lymphoid Nodal (N) status
N0 14 4 10 8
N1-3 39 49 0.010* 44 44 0.866
TNM Clinical stage
I + II 18 20 19 19
III+IVa+IVb 35 33 0.685 35 33 0.885
LMP1
- 23 33 30 26
+ 27 20 0.098 22 25 0.494
Open in a new tab

Note. *P < 0.05, as determined by the Pearson chi2 test.

Immunohistochemical variables and survival evaluation

Of these 106 NPC patients, Kaplan-Meier and log-rank test analyses indicated that the groups with Foxp3+TIL>77.2 cells/HPF (median, n = 53) had a significantly better overall survival (OS, 65 vs. 56 months, median/5 year, P = 0.01) and progression-free survival (PFS, 64 vs. 52 months, median/5 year, P = 0.002) when compared to the groups with Foxp3+TIL = 77.2 cells/HPF (median, n = 53) (Fig 2). However, the number of CD8+, GrB+ or IL-17+ TIL is not significantly associated with OS or PFS (data not shown). Upon univariate analysis, age, sex, LMP1 expression, and densities of CD8+TIL, GrB+TIL and IL-17+TIL showed no prognostic significance for OS and PFS. In contrast, tumor size, lymphoid nodal status, TNM clinical stage and the density of Foxp3+TIL were predictors for OS and PFS (Additional File 2). Furthermore, the multivariate Cox proportional hazards analysis of covariates displayed P < 0.05 in univariate analysis (tumor size, lymphoid nodal status, TNM clinical stage and the number of Foxp3+TIL) indicating that after backward elimination, Foxp3 becomes a strong independent favorable prognostic factor for OS and PFS (P < 0.01, Table 5).

Figure 2.

Figure 2

Open in a new tab

Results of survival rate with immunohistochemical variables. Individually, the number of Foxp3+ cells (A and D), the ratio of CD8+TIL to Foxp3+ TIL (B and E) and Foxp3 together with GrB+ cells (C and F) are significantly associated with the overall survival (OS, P < 0.005) and progression-free survival (PFS, P < 0.005) in NPC patients.

Table 5.

Multivariate analysis of factors and Foxp3+ TIL associated with survival

Variables OS (n = 106) PFS (n = 106)
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Tumor (T) stage (4+3/2+1) 0.803 0.331-1.949 0.627 0.930 0.408-2.119 0.863
Nodal (N) status (3+2+1/0) 5.181 0.679-40.071 0.115 3.880 0.886-16.994 0.072
TNM stage (III+IVa+IVb/I+II) 2.582 0.798-8.351 0.113 1.704 0.622-4.674 0.300
Foxp3+ TILs (high/low) 0.378 0.170-0.841 0.017* 0.331 0.161-0.682 0.003*
Open in a new tab

NOTE: The Cox proportional hazards regression model was used in univariate analysis.

The multivariate Cox proportional hazards assessment indicated that the ratio of CD8 to Foxp3 is an independent feature in the PFS survival of patients (RH = 2.39, P = 0.016) and the combination of Foxp3 and GrB is also an independent prognostic factor in NPC (Table 6). The high expression of Foxp3 and GrB correlated with better OS (66 vs. 51 months, median/5 year) and PFS (64 vs. 46 months, median/5 year) compared to low expression of Foxp3 and GrB (RH<1, P < 0.01) (Fig 2).

Table 6.

Multivariate analysis of factors for the ratio of CD8+ TIL to Foxp3+ TIL and Foxp3+ TIL combined with Granzyme B+ TIL with survival

Variables OS (n = 106) PFS (n = 106)
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
The ratio of CD8 to Foxp3
Tumor (T) stage (4+3/2+1) 1.007 0.419-2.420 0.988 1.185 0.523-2.686 0.685
Nodal (N) status (3+2+1/0) 4.172 0.545-31.939 0.169 2.821 0.655-12.154 0.164
TNM stage (III+IVa+IVb/I+II) 2.444 0.754-7.928 0.136 1.561 0.569-4.286 0.387
CD8/Foxp3 (high/low) 1.898 0.885-4.071 0.100 2.393 1.174-4.874 0.016*
Combination of Foxp3 and GrB
Tumor (T) stage (4+3/2+1) 0.647 0.256-1.639 0.359 0.750 0.318-1.768 0.510
Nodal (N) status (3+2+1/0) 5.798 0.757-44.421 0.091 4. 681 1.080-20.280 0.039*
TNM stage (III+IVa+IVb/I+II) 3.078 0.940-10.075 0.063 2.093 0.759-5.78 0.153
Combination of Foxp3+ and Granzyme B+ TIL
Overall NA 0.028* NA 0.001*
Foxp3GrB high VS Foxp3GrB low 0.314 0.111-0.887 0.029* 0.197 0.072-0.540 0.002*
Open in a new tab

Note: *significant. Abbreviations: CI, confidence interval; OS, overall survival; PFS, progression-free survival; NA, not applicable.

Immunohistochemical variables and survival evaluation in the patients with different disease stages

To further evaluate the association between different lymphocyte variables and the patient outcome, we classified the patients by their clinical stages: early disease (stages I and II, n = 38) and late disease (stages III and IV, n = 68). We assessed the correlation between the density of CD8, GrB, Foxp3 and IL-17 positive TIL and patient outcome in different disease stages. Our results showed that, in early disease stage patients, a higher number of CD8+TIL was significantly associated with poor PFS (P = 0.025) without significant association with OS. A higher ratio of CD8 to Foxp3 was also found to be significantly associated with poor OS and PFS (P = 0.041 and 0.001, respectively, Fig 3A). However, the aforementioned factors did not significantly impact OS or PFS in late stage patients (data not shown). In contrast, a higher Foxp3+TIL number was significantly associated with a better OS (P = 0.012) and PFS (P = 0.001) in late stage patients (Fig 3B), but had no significant influence on OS and PFS in early stage patients. Additionally, the combination of tumor infiltrating Foxp3+ cells and GrB+ activated CTL was associated with the survival of late stage patients: a higher number of Foxp3+ and GrB+ cells was associated with a longer OS and PFS compared to a lower number of Foxp3+ and GrB+ cells (P < 0.001, Fig 3B).

Figure 3.

Figure 3

Open in a new tab

Results of survival rate with immunohistochemical variables in different disease stages (n = 39). A. In the early disease stage, the number of CD8+ cells (A and C) and the ratio of CD8+TIL to Foxp3+ TIL (B and D) are significantly associated with PFS (P < 0.05). B. In the late disease stage, the number of Foxp3+ cells (A and C) and Foxp3+ together with GrB+ cells (B and D) are significantly associated with OS (P < 0.01) and PFS (P < 0.01).

Discussion

To better understand the special immunological state of the inflammatory background in NPC and its contribution to the clinicopathological characteristics and prognosis of NPC patients, we characterized the T cell infiltrating lymphocytes in a series of cases by immunohistochemical staining with antibodies specific to CTL, activated CTL, Treg and Th17 subsets. We have demonstrated that the number of Foxp3+TIL (Treg) was significantly associated with a favorable outcome (OS and PFS) in Chinese NPC patients (Fig 2); this association was correlated with the disease stage since Foxp3 was a favorable factor for survival in late stage patients but no significant influence on the early stage patients (Fig 3B, P < 0.01). Furthermore, multivariate Cox proportional hazards analysis indicated that Foxp3 was a strong favorable prognostic factor for OS and PFS for all patients (HR = 0.233, P < 0.01, Table 5). Our result is in line with published reports that the Foxp3+TIL is positively associated with better survival in EBV-associated classic Hodgkin lymphoma and follicular lymphoma [29,30]. Due to their ability to suppress naïve T cells and effector T cells, Treg cells are usually defined as immune suppression cells that inhibit antitumor immunity and help tumor cell immune evasion. Some studies even found that the number of tumor infiltrating Foxp3+Treg cells was completely associated with poor survival in several kinds of solid carcinoma such as ovarian and cervical cancers [15,31-34]. Since it is difficult to define the general function of Treg cells in all types of cancer, we suggest that the function of Treg in the tumor microenvironment should be specifically analyzed in different malignancies. Undifferentiated NPC is associated with EBV infection. The virus antigens expressed in the tumor cell are neo-antigens recognized by host immune cells, so many different lymphocytes are homing to tumor tissues including CD8+ T cells, CD4+ T cells and other immune cells. The possible role of Tregs in controlling immune response in the NPC microenvironment to prevent lymph node spreading of the cancer cell is worthy of recognition. A recent study also demonstrated that the Foxp3+ Treg cells could facilitate early immune responses to local viral infection at least in part by orchestrating a timely homing of immune effector cells to the site of infection [35]. In our study, the ratio of CD8+TIL to Foxp3+TIL (CTL/Treg cells) was significantly associated with poor OS and PFS in early stage patients (Fig 3A), but had no effect on late stage patients, implying that increased number of Foxp3+Treg cell together with decrease number of CD8+CTL could suppress tumor growth and lymph node metastasis at the early-stage of NPC (high CD8+TIL number is positively associated with N stage in Table 3). There are three types of Treg including thymic-derived naturally-occurring Tregs (nTreg), antigen-induced Tregs (iTreg) and TGFβ+ Treg cells (Th3). The mechanisms of suppressing proliferation of naïve or effector T cells of these Treg cells are controlled by cell-to-cell contact or secreting cytokines IL-10 and TGFβ [36-42]. However, it has been reported that these Treg cell subpopulations are unstable in vivo and able to shift to IL-17 secreting cells[4,43,44]. Moreover, the anti-tumor role of these subset cells has not been clarified. However, it has been identified that some tumor derived Treg cells with the tumor antigen specificity could recognize the autologous antigen specific tumor cell and secret IFNγ in vitro [45]. In the present study, we found that a high density of Treg (Foxp3+TIL) was a favorable factor, while the increased number of CD8+ CTL was not a favorable factor in NPC patients. We are currently evaluating the functions and related mechanism of Foxp3+Treg cell derived from NPC TILs by in vitro and animal experiment.

The cytotoxic T cell (CTL) has been assigned an important role in antitumor immunity, but in our results the CD8+ CTL density was positively associated with poor PFS (Fig 3A) in early stage patients, and with the lymphoid nodal spreading (Table 3). This result was unexpected; however, we have previously found that the CD8+TIL from NPC patients failed to release IFNγ by the stimulation of autologous EBV-specific antigen cells in vitro [46]. Therefore, a possible explanation for this result is that a CD8+ CTL function is impaired thus the CD8+ CTL could not kill the tumor cell in NPC TIL. Another possibility is that the acute immune response could induce the spreading of tumor cells to the regional lymphoid node. To further evaluate the function of tumor infiltrating CTL in NPC, we detected Granzyme B positive activated CTL in TIL. In our data, the The number of activated CTL (GrB+TIL) is negatively associated with tumor stage (the same as Treg) and significantly decreased in the senior age patient group (P < 0.01, Table 3). However, the higher number of activated CTL seems to correlate with better OS and PFS in total NPC patients (P = 0.14 and 0.10, respectively) and in late disease stage patients (P = 0.19 and 0.08, respectively) although no statistical significance was found (data not shown). Our further evaluation of the correlation and imbalance of CTL and Treg cell in NPC TIL showed that the ratio of CD8/Foxp3 was significantly associated with poorer OS and PFS in early stage patients (P = 0.04 and 0.001, respectively). When we evaluated the impact of the combination of Treg and activated CTL densities, our results showed that the higher density of Treg and activated CTL was associated with better survival in total and late stage patients (OS P = 0.005 and 0.015, respectively; PFS P = 0.001 and 0.003, respectively). One published report in 2002 showed that the number of activated CTL was associated with a rapid fatal outcome in 43 NPC patients [47]; another published report in 2009 showed that the number of Treg cells was increased while the expression of the ζ-chain decresed in NPC tumor tissues compared to normal nasopharynx tissues[48]. Our results seem to contradict these finding, but the discrapensy may be due to differences in sample sizes and racial origins.

In order to understand the role of the CD8+Foxp3+Treg and GrB+Foxp3+ activated Treg cell subsets in NPC tumor tissues, we double stained CD8 and Foxp3, and GrB and Foxp3. The CD8+Foxp3+ and GrB+Foxp3+ TIL were in small number (1.39 ± 0.9 cells/HPF and 3.52 ± 2 cells/HPF, respectively) compared to the total TIL. We found that the number of CD8 and Foxp3 double positive TIL was positively correlated with tumor lymphoid nodal metastasis in NPC patients (P = 0.006) (the same as CD8+TILs). However, no correlation between GrB+Foxp3+TIL and clinicopathological characteristic NPC patients was found (Table 4). Although many publications have showed that the expression of Granzyme B is a marker of activated Treg and the activity of Treg is dependent on the Granzyme B pathway [49,50], it remains difficult to define the function of the GrB+Foxp3+ subset in NPC.

In total human CD4+ T cells, in addition to the traditional Th1 and Th2 helper T cell subsets, Treg and Th17 cell populations have also been identified. The Th17 cell is newly characterized by secretion of IL-17, IL-22, and IL-21 with or without IFN-γ, and its function is opposite to that of the Treg cell in autoimmune disease since Th17 cells usually promote inflammatory processes [51-54]. The characteristic of Th17 cells in NPC is unknown. We therefore detected the IL-17+TIL by double staining of IL-17 and Foxp3. We could not find IL-17+Foxp3+TIL by IHC staining in vivo, although there are several recent reports of the in vitro detection of Il-17 and Foxp3 double positive cells in human [4,55]. We also found IL-17-secreting T clones highly expressing Foxp3, and with the suppression function to naïve T cells from NPC TIL in vitro (unpublished data), the failure to find the double IL-17 and Foxp3 positive TIL in NPC may be due to the lack of sensitivity of the IHC staining method or the differences between in vivo and in vitro conditions. In our study, no correlation between the number of IL-17+TIL and the clinicopathological characteristics was found (Table 3). We also could not find a significant association between the number of IL-17+TIL and outcome of patients by univariate analysis (See additional file 2) although it seems that a higher number of IL-17+TIL was associated with better OS and PFS of patients (P = 0.19 and 0.39, data not shown); however, this association was not statistically significant. Recently, Zou and colleagues also reported that in ovarian cancer the number of Th17 cells was associated with a better outcome [56].

Conclusions

Our present study found that the tumor infiltrating Foxp3+ Treg cell was an independent favorable factor for the T stage and for survival in the NPC patients, while the tumor infiltrating CD8+, GrB+ or IL-17+ cells was not an independent factor for survival. Furthermore, the ratio of CD8+TIL to Foxp3+TIL was significantly associated with poor OS and PFS in all NPC patients and poor PFS in the patients with early stage diseases, and was an independent factor for PFS in multivariate analyses. Our results support the assumption that the Treg cell but not the CTL take a favorable role in anti-tumor immunity of the NPC patients. These could be explained by the impaired function of CTLs in NPC patients. Our finding that the combination of Foxp3+TIL and GrB+TIL (activated CTL) was an independent favorable factor and was significantly associated with improved outcomes of OS and PFS in the patients with late-stage disease further support the assumption of the favorable role of Treg in NPC patients. In conclusion, our study discloses contrasting roles of tumor infiltrating lymphocyte subsets in the immunomodulation of NPC, and gives some support for the new strategy choice of immunotherapy for NPC.

Methods

Tissue specimens

Formalin-fixed, paraffin-embedded tissues from 106 NPC patients were used. The NPC biopsy specimens were collected between 2002 and 2003 at the Sun Yat-sen University Cancer Center. Adequate clinical follow-up data were available in these patients. NPC were classified histologically into three types according to WHO classification: squamous cell carcinoma (SCC, type I), non-keratinizing carcinoma (NKC, type II) and undifferentiated carcinoma (UC, type III). The disease stage of each patient was classified by the 2002 AJCC staging system [57]. The characteristics of the NPC patients are shown in Table 1. This study was conducted in accordance with the Helsinki Declaration, and all patients signed a consent form approved by the Research Ethics Committee of the Sun Yat-sen University Cancer Center.

Immunohistochemistry

The paraffin-embedded tissues were sectioned continuously at a thickness of 4 μm. The co-expression of FoxP3 with CD8 and of Granzyme B with IL-17 were detected by sequential double-immunohistochemical staining according to the instructions of the double-staining EnVison™ G/2 Doublestain System (DakoCytomation, Glostrup, Denmark), or using the EnVison™ Detection Kit (DakoCytomation, Glostrup, Denmark) for LMP1. In brief, the tissue sections were deparaffinized and then rehydrated through graded alcohols, sections were immersed into preheated EDTA (PH 8.0). Antigen retrieval were performed by microwave (95°C for 10 min for LMP1; 95°C for 18 min for other antigens), and then allowed to cool to room temperature. Endogenous peroxidase and alkaline phosphatase activities were blocked with dual endogenous enzyme block reagent from the doublestain kit, and nonspecific binding sites were blocked with goat serum at room temperature for 20 min. Primary antibodies including mouse monoclonal anti-EBV LMP1(Clone CS.1-4, DAKO, Glostrup, Denmark; diluted at 1:80), mouse anti-human CD8(Clone CD8/144B, DAKO, Glostrup, Denmark; diluted at 1:40), mouse anti-human Granzyme B (clone GrB-7, Glostrup, Denmark; diluted at 1:25), mouse anti-human Foxp3(Clone 221D/D3, Santa Cruz Biotechnology, CA, USA, diluted at 1:100), and goat monoclonal anti-human IL-17(R&D Systems, Abingdon, UK; diluted at 1:300) were incubated at 4°C overnight, and developed with peroxidase and 3,3'-diaminobenzidine tetrahydrochloride (brown), or permanment red (red).

Data were obtained by counting the positively stained lymphocytes in 5 separate 400× high-power microscopic fields (HPFs) and calculating the mean number of positively stained cells per HPF. Mouse IgG1 (DAKO) and normal goat IgG (Santa) negative control stains were generated and evaluated.

Statistical Analysis

All data analysis was carried out with the SPSS 13.0 software (SPSS, Chicago, IL, USA). The median value was used to cut off the subgroups of all immunohistochemical variables in our data. The Pearson chi2 test was carried out to assess the relationship among lymphocytic variables and clinicopathological characteristics. Two-tailed P < 0.05 was judged to be significant.

Overall survival (OS) was defined as the period from initial diagnosis to death by any cause; progression-free survival was defined as time from initial diagnosis to the progression of NPC or death by any cause. Cumulative survival time was calculated by the Kaplan-Meier method and analyzed by the log-rank test. Univariate and multivariate analyses were based on the Cox proportional hazards regression model.

Abbreviations

The abbreviations used are: NPC: Nasopharyngeal Carcinoma; TIL: Tumor infiltrating lymphocytes; GrB: Granzyme B; Foxp3: Forkhead Box P3; CTL: Cytotoxic T lymphocytes; Treg: Regulatory T cells; OS: Overall survival; PFS: Progression-free survival; IHC: Immunohistochemical staining; HPF: High-power field; SSC: squamous cell carcinoma; NKC: non-keratinizing carcinoma; UC: undifferentiated carcinoma; VS: versus; CI: confidence interval; NA: not applicable.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

LNZ performed the immunohistochemical staining and stastical analysis; JL designed the experiment, analyzed the data and wrote the manuscript; HYM and FQ collected the samples and clinic data; LMZ and CNQ modified and revised the manuscript; YXZ supervised in the design of the study and finalized the manuscript. All authors read and approved the final manuscript.

Supplementary Material

Additional file 1

The record of experiment and clinical data for each NPC patient. All results for Description: immunochemical variables and clinical information, fellow-up data for each patient were shown in this excel file.

Click here for file (74KB, XLS)
Additional file 2

Univariate analyses of factors associated with survival of patients. The Description: univarate statistic analyses for the association of age, gender, TNM stage and immunochemical variables including LMP1, CD8, GrB, Foxp3 and IL-17 and the survival of patients.

Click here for file (41KB, DOC)

Contributor Information

Yi-Lan Zhang, Email: lanzi1997@yahoo.com.cn.

Jiang Li, Email: lijiang2@mail.sysu.edu.cn.

Hao-Yuan Mo, Email: mohaoyuan1964@tom.com.

Fang Qiu, Email: qiufang6138@163.com.

Li-Min Zheng, Email: zhenglm@mail.sysu.edu.cn.

Chao-Nan Qian, Email: qianchn@sysucc.org.cn.

Yi-Xin Zeng, Email: zengyix@mail.sysu.edu.cn.

Acknowledgements

This study was supported by National Natural Science Fund 224 (30872981) of China.

References

  1. Guigay J, Temam S, Bourhis J, Pignon JP, Armand JP. Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy. Ann Oncol. 2006;17(Suppl 10):x304–307. doi: 10.1093/annonc/mdl278. [DOI] [PubMed] [Google Scholar]
  2. Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer. 2005;103:22–31. doi: 10.1002/cncr.20768. [DOI] [PubMed] [Google Scholar]
  3. Sanguineti G, Bossi P, Pou A, Licitra L. Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol) 2003;15:451–460. doi: 10.1016/s0936-6555(03)00201-2. [DOI] [PubMed] [Google Scholar]
  4. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, Valmori D. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci USA. 2009;106:8635–8640. doi: 10.1073/pnas.0900621106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041–2054. doi: 10.1016/S0140-6736(05)66698-6. [DOI] [PubMed] [Google Scholar]
  6. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757–768. doi: 10.1038/nrc1452. [DOI] [PubMed] [Google Scholar]
  7. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal cancer. Cancer Treat Res. 2003;114:275–293. doi: 10.1007/0-306-48060-3_11. full_text. [DOI] [PubMed] [Google Scholar]
  8. Zeng YX, Jia WH. Familial nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12:443–450. doi: 10.1016/S1044579X02000871. [DOI] [PubMed] [Google Scholar]
  9. Lakhdar M, Ben Aribia MH, Maalej M, Ladgham A. Selective homing of phenotypically lytic cells within nasopharyngeal carcinoma biopsies: numerous CD8- and CD16-positive cells in the tumor. Int J Cancer. 1991;48:57–61. doi: 10.1002/ijc.2910480111. [DOI] [PubMed] [Google Scholar]
  10. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macri L, Daniele L, Oliaro A. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009;87:365–371. doi: 10.1016/j.athoracsur.2008.10.067. discussion 371-362. [DOI] [PubMed] [Google Scholar]
  11. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, Zee AG van der, Daemen T, Nijman HW. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58:449–459. doi: 10.1007/s00262-008-0583-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2008;108:415–420. doi: 10.1016/j.ygyno.2007.10.016. [DOI] [PubMed] [Google Scholar]
  13. Dunn GP, Dunn IF, Curry WT. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun. 2007;7:12. [PMC free article] [PubMed] [Google Scholar]
  14. Couzin J. Cancer. T cells a boon for colon cancer prognosis. Science. 2006;313:1868–1869. doi: 10.1126/science.313.5795.1868b. [DOI] [PubMed] [Google Scholar]
  15. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102:18538–18543. doi: 10.1073/pnas.0509182102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H, Barten M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol. 2004;35:808–816. doi: 10.1016/j.humpath.2004.01.022. [DOI] [PubMed] [Google Scholar]
  17. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28:e26–31. doi: 10.1097/00006676-200401000-00023. [DOI] [PubMed] [Google Scholar]
  18. Sobhani I, Le Gouvello S. Critical role for CD8+FoxP3+ regulatory T cells in colon cancer immune response in humans. Gut. 2009;58:743–744. doi: 10.1136/gut.2008.175521. [DOI] [PubMed] [Google Scholar]
  19. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–192. doi: 10.1200/JCO.2008.18.7229. [DOI] [PubMed] [Google Scholar]
  20. Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, Ryder LP, Ralfkiaer E. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia. 2007;21:2512–2518. doi: 10.1038/sj.leu.2404913. [DOI] [PubMed] [Google Scholar]
  21. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132:2328–2339. doi: 10.1053/j.gastro.2007.03.102. [DOI] [PubMed] [Google Scholar]
  22. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006;86:231–245. doi: 10.1038/labinvest.3700389. [DOI] [PubMed] [Google Scholar]
  23. Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, Ohta M, Kitano S, Mori M. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol. 2008;34:173–179. doi: 10.1016/j.ejso.2007.08.008. [DOI] [PubMed] [Google Scholar]
  24. Yoshioka T, Miyamoto M, Cho Y, Ishikawa K, Tsuchikawa T, Kadoya M, Li L, Mishra R, Ichinokawa K, Shoji Y, Matsumura Y, Shichinohe T, Hirano S, Shinohara T, Itoh T, Kondo S. Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer. 2008;98:1258–1263. doi: 10.1038/sj.bjc.6604294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, Lee JH, Yim CY, Kwak JY. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma. 2008;49:247–256. doi: 10.1080/10428190701824536. [DOI] [PubMed] [Google Scholar]
  26. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res. 2006;12:3355–3360. doi: 10.1158/1078-0432.CCR-05-2434. [DOI] [PubMed] [Google Scholar]
  27. Gottschalk S, Bollard CM, Straathof KC, Louis CU, Savoldo B, Dotti G, Brenner MK, Heslop HE, Rooney CM. T cell therapies. Ernst Schering Found Symp Proc. 2006. pp. 69–82. [DOI] [PubMed]
  28. Chan AT, Teo PM, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol. 2004;31:794–801. doi: 10.1053/j.seminoncol.2004.09.008. [DOI] [PubMed] [Google Scholar]
  29. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93:193–200. doi: 10.3324/haematol.11702. [DOI] [PubMed] [Google Scholar]
  30. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, Montserrat E, Campo E, Banham AH. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957–2964. doi: 10.1182/blood-2006-04-018218. [DOI] [PubMed] [Google Scholar]
  31. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005;11:8326–8331. doi: 10.1158/1078-0432.CCR-05-1244. [DOI] [PubMed] [Google Scholar]
  32. Bhairavabhotla RK, Verm V, Tongaonkar H, Shastri S, Dinshaw K, Chiplunkar S. Role of IL-10 in immune suppression in cervical cancer. Indian J Biochem Biophys. 2007;44:350–356. [PubMed] [Google Scholar]
  33. Visser J, Nijman HW, Hoogenboom BN, Jager P, van Baarle D, Schuuring E, Abdulahad W, Miedema F, Zee AG van der, Daemen T. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol. 2007;150:199–209. doi: 10.1111/j.1365-2249.2007.03468.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Molling JW, de Gruijl TD, Glim J, Moreno M, Rozendaal L, Meijer CJ, Eertwegh AJ van den, Scheper RJ, von Blomberg ME, Bontkes HJ. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer. 2007;121:1749–1755. doi: 10.1002/ijc.22894. [DOI] [PubMed] [Google Scholar]
  35. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science. 2008;320:1220–1224. doi: 10.1126/science.1155209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83–117. doi: 10.1146/annurev.immunol.021908.132544. [DOI] [PubMed] [Google Scholar]
  37. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity. 2009;30:626–635. doi: 10.1016/j.immuni.2009.05.002. [DOI] [PubMed] [Google Scholar]
  38. van Maren WW, Jacobs JF, de Vries IJ, Nierkens S, Adema GJ. Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology. 2008;124:445–452. doi: 10.1111/j.1365-2567.2008.02871.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Moutsopoulos NM, Wen J, Wahl SM. TGF-beta and tumors--an ill-fated alliance. Curr Opin Immunol. 2008;20:234–240. doi: 10.1016/j.coi.2008.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Gallimore A, Godkin A. Regulatory T cells and tumour immunity - observations in mice and men. Immunology. 2008;123:157–163. doi: 10.1111/j.1365-2567.2007.02748.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Barnett BG, Ruter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol. 2008;622:255–260. doi: 10.1007/978-0-387-68969-2_20. full_text. [DOI] [PubMed] [Google Scholar]
  42. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol. 2007;19:217–223. doi: 10.1016/j.coi.2007.02.004. [DOI] [PubMed] [Google Scholar]
  43. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol. 2009;21:281–285. doi: 10.1016/j.coi.2009.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity. 2009;30:646–655. doi: 10.1016/j.immuni.2009.05.001. [DOI] [PubMed] [Google Scholar]
  45. Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol. 2005;174:2661–2670. doi: 10.4049/jimmunol.174.5.2661. [DOI] [PubMed] [Google Scholar]
  46. Li J, Zeng XH, Mo HY, Rolen U, Gao YF, Zhang XS, Chen QY, Zhang L, Zeng MS, Li MZ, Huang WL, Wang XN, Zeng YX, Masucci MG. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One. 2007;2:e1122. doi: 10.1371/journal.pone.0001122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Oudejans JJ, Harijadi H, Kummer JA, Tan IB, Bloemena E, Middeldorp JM, Bladergroen B, Dukers DF, Vos W, Meijer CJ. High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol. 2002;198:468–475. doi: 10.1002/path.1236. [DOI] [PubMed] [Google Scholar]
  48. Yip WK, Abdullah MA, Yusoff SM, Seow HF. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Clin Exp Immunol. 2009;155:412–422. doi: 10.1111/j.1365-2249.2008.03793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27:635–646. doi: 10.1016/j.immuni.2007.08.014. [DOI] [PubMed] [Google Scholar]
  50. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6:338–344. doi: 10.1038/ni1180. [DOI] [PubMed] [Google Scholar]
  51. Yang J, Chu Y, Yang X, Gao D, Zhu L, Wan L, Li M. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1472–1483. doi: 10.1002/art.24499. [DOI] [PubMed] [Google Scholar]
  52. Mihara M, Ohsugi Y, Kishimoto T. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody. Biofactors. 2009;35:47–51. doi: 10.1002/biof.9. [DOI] [PubMed] [Google Scholar]
  53. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol. 2007;19:652–657. doi: 10.1016/j.coi.2007.07.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24:677–688. doi: 10.1016/j.immuni.2006.06.002. [DOI] [PubMed] [Google Scholar]
  55. Voo KS, Wang YH, Santori FR, Boggiano C, Arima K, Bover L, Hanabuchi S, Khalili J, Marinova E, Zheng B, Littman DR, Liu YJ. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA. 2009;106:4793–4798. doi: 10.1073/pnas.0900408106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W. Phenotype, distribution, generation, functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141–9. doi: 10.1182/blood-2009-03-208249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Chan AT, Felip E. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii81–82. doi: 10.1093/annonc/mdn098. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Additional file 1

The record of experiment and clinical data for each NPC patient. All results for Description: immunochemical variables and clinical information, fellow-up data for each patient were shown in this excel file.

Click here for file (74KB, XLS)
Additional file 2

Univariate analyses of factors associated with survival of patients. The Description: univarate statistic analyses for the association of age, gender, TNM stage and immunochemical variables including LMP1, CD8, GrB, Foxp3 and IL-17 and the survival of patients.

Click here for file (41KB, DOC)

Articles from Molecular Cancer are provided here courtesy of BMC

RESOURCES